ATE309338T1 - Antisense oligonucleotides zur inhibition der expression von type i procollagen - Google Patents
Antisense oligonucleotides zur inhibition der expression von type i procollagenInfo
- Publication number
- ATE309338T1 ATE309338T1 AT00988966T AT00988966T ATE309338T1 AT E309338 T1 ATE309338 T1 AT E309338T1 AT 00988966 T AT00988966 T AT 00988966T AT 00988966 T AT00988966 T AT 00988966T AT E309338 T1 ATE309338 T1 AT E309338T1
- Authority
- AT
- Austria
- Prior art keywords
- expression
- procollagen
- inhibition
- type
- antisense oligonucleotides
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 title 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 108020004491 Antisense DNA Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003816 antisense DNA Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9929487.8A GB9929487D0 (en) | 1999-12-15 | 1999-12-15 | Antisense oligonucleotides |
| PCT/GB2000/004741 WO2001044455A2 (en) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides for the inhibition of expression of type i procollagen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE309338T1 true ATE309338T1 (de) | 2005-11-15 |
Family
ID=10866254
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00988966T ATE309338T1 (de) | 1999-12-15 | 2000-12-12 | Antisense oligonucleotides zur inhibition der expression von type i procollagen |
| AT05024183T ATE410510T1 (de) | 1999-12-15 | 2000-12-12 | Antisense oligonukleotide zur expressionshemmung des typ i-prokollagens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05024183T ATE410510T1 (de) | 1999-12-15 | 2000-12-12 | Antisense oligonukleotide zur expressionshemmung des typ i-prokollagens |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7173122B2 (de) |
| EP (3) | EP2025752A3 (de) |
| JP (1) | JP2003516752A (de) |
| KR (1) | KR20020064936A (de) |
| CN (1) | CN1423695A (de) |
| AT (2) | ATE309338T1 (de) |
| AU (1) | AU2529701A (de) |
| BR (1) | BR0016347A (de) |
| CA (1) | CA2390674A1 (de) |
| DE (2) | DE60023943T2 (de) |
| GB (1) | GB9929487D0 (de) |
| IL (1) | IL149640A0 (de) |
| MX (1) | MXPA02005871A (de) |
| NO (1) | NO20022799D0 (de) |
| NZ (1) | NZ519008A (de) |
| WO (1) | WO2001044455A2 (de) |
| ZA (1) | ZA200203878B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396823B2 (en) * | 1999-12-15 | 2008-07-08 | Nath Rahul K | Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis |
| CN111378657B (zh) * | 2018-12-28 | 2024-03-15 | 苏州瑞博生物技术股份有限公司 | 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
| WO1993011149A1 (en) | 1991-12-03 | 1993-06-10 | Thomas Jefferson University | Methods of detecting a genetic predisposition for osteoporosis |
| WO1994011494A1 (en) | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
| CA2159195A1 (en) * | 1993-03-26 | 1994-10-13 | Darwin J. Prockop | Use of a col 1a1 mini-gene construct to inhibit collagen synthesis |
| DE59607750D1 (de) * | 1995-03-13 | 2001-10-31 | Aventis Pharma Gmbh | Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19508923A1 (de) * | 1995-03-13 | 1996-09-19 | Hoechst Ag | Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| EP0736608A1 (de) * | 1995-04-08 | 1996-10-09 | Roche Diagnostics GmbH | Verfahren zur spezifischen Vervielfältigung und zum Nachweis von DNA bzw. RNA |
| EP0856579A1 (de) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US6007995A (en) * | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| BR0015507A (pt) * | 1999-11-12 | 2002-10-22 | Fibrogen Inc | Gelatinas e colágenos animais |
-
1999
- 1999-12-15 GB GBGB9929487.8A patent/GB9929487D0/en not_active Ceased
-
2000
- 2000-12-12 AT AT00988966T patent/ATE309338T1/de not_active IP Right Cessation
- 2000-12-12 AU AU25297/01A patent/AU2529701A/en not_active Abandoned
- 2000-12-12 EP EP08017586A patent/EP2025752A3/de not_active Withdrawn
- 2000-12-12 AT AT05024183T patent/ATE410510T1/de not_active IP Right Cessation
- 2000-12-12 CN CN00817282A patent/CN1423695A/zh active Pending
- 2000-12-12 CA CA002390674A patent/CA2390674A1/en not_active Abandoned
- 2000-12-12 KR KR1020027007591A patent/KR20020064936A/ko not_active Withdrawn
- 2000-12-12 BR BR0016347-3A patent/BR0016347A/pt not_active Application Discontinuation
- 2000-12-12 JP JP2001545532A patent/JP2003516752A/ja active Pending
- 2000-12-12 IL IL14964000A patent/IL149640A0/xx unknown
- 2000-12-12 DE DE60023943T patent/DE60023943T2/de not_active Expired - Lifetime
- 2000-12-12 DE DE60040495T patent/DE60040495D1/de not_active Expired - Lifetime
- 2000-12-12 NZ NZ519008A patent/NZ519008A/en unknown
- 2000-12-12 US US10/149,352 patent/US7173122B2/en not_active Expired - Fee Related
- 2000-12-12 WO PCT/GB2000/004741 patent/WO2001044455A2/en not_active Ceased
- 2000-12-12 EP EP00988966A patent/EP1244781B1/de not_active Expired - Lifetime
- 2000-12-12 EP EP05024183A patent/EP1698695B1/de not_active Expired - Lifetime
- 2000-12-12 MX MXPA02005871A patent/MXPA02005871A/es unknown
-
2002
- 2002-05-15 ZA ZA200203878A patent/ZA200203878B/xx unknown
- 2002-06-12 NO NO20022799A patent/NO20022799D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02005871A (es) | 2002-10-23 |
| EP1698695A2 (de) | 2006-09-06 |
| DE60023943D1 (de) | 2005-12-15 |
| EP1698695B1 (de) | 2008-10-08 |
| KR20020064936A (ko) | 2002-08-10 |
| WO2001044455A2 (en) | 2001-06-21 |
| EP1244781A2 (de) | 2002-10-02 |
| NZ519008A (en) | 2004-04-30 |
| GB9929487D0 (en) | 2000-02-09 |
| ATE410510T1 (de) | 2008-10-15 |
| CA2390674A1 (en) | 2001-06-21 |
| US7173122B2 (en) | 2007-02-06 |
| BR0016347A (pt) | 2002-09-10 |
| DE60023943T2 (de) | 2006-08-03 |
| AU2529701A (en) | 2001-06-25 |
| EP2025752A2 (de) | 2009-02-18 |
| WO2001044455A3 (en) | 2002-01-10 |
| EP2025752A3 (de) | 2009-08-12 |
| EP1698695A3 (de) | 2007-02-14 |
| US20030105050A1 (en) | 2003-06-05 |
| NO20022799L (no) | 2002-06-12 |
| JP2003516752A (ja) | 2003-05-20 |
| ZA200203878B (en) | 2003-08-15 |
| DE60040495D1 (de) | 2008-11-20 |
| EP1244781B1 (de) | 2005-11-09 |
| CN1423695A (zh) | 2003-06-11 |
| NO20022799D0 (no) | 2002-06-12 |
| IL149640A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
| EP1009860A4 (de) | Antisense oligonukleotid zur inhibierung von ras | |
| ATE221914T1 (de) | Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung | |
| DE69730315D1 (de) | Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression | |
| EP1750771A4 (de) | Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung | |
| DE50214715D1 (de) | Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression | |
| ATE428780T1 (de) | Verfahren zur zubereitung von antisense oligonukleotiden | |
| DK3222722T3 (da) | Antisense-design | |
| DK0920498T3 (da) | Hamster EF-1alfa transskriptionelt, regulatorisk DNA | |
| EP1569695A4 (de) | Antisense-modulationder apolipoprotein-b-expression | |
| DE60043470D1 (de) | Pflanzliche Defensine | |
| DE60023943D1 (de) | Antisense oligonucleotides zur inhibition der expression von type i procollagen | |
| ATE423129T1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
| ATE369422T1 (de) | Antisense-oligonukleotid zur hemmung der melanom- inhibierenden aktivität (mia) | |
| SE0302965D0 (sv) | Hämmare av DNA-Metyltransferasisoformer | |
| EP1118659A4 (de) | Expressionssysteme zur funktionellen expression von nukleinsäuren | |
| TW200502244A (en) | Expression of zebrafish bone morphogenetic protein 4 | |
| DE59910945D1 (de) | Hemmung von alopezie | |
| CY1114199T1 (el) | Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β | |
| ATA197498A (de) | Verfahren zur oxidation von methyl-, methylen- oder methingruppen enthaltenden substraten | |
| ATA112799A (de) | Verfahren zur oxidation von methyl-, methylen- oder methingruppen enthaltenden substraten | |
| WO2003057846A3 (en) | Methods and materials for modulating task-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1244781 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |